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WHERE WE STARTED
The description of factor-dependent cyto-
toxic T-cell lines in the late 1970s trans-
formed T-cell biology (1). Among other
events, it led to the cloning of a cDNA
encoding IL-2 (2). It also led to the identi-
fication of T-cell subsets and formulation
of the Th1/Th2 concept in the 80s (3).
However, comparable advances in B-cell
biology were lacking, partly because of the
lack of availability of factor-dependent B-
cell lines. This was the case despite the fact
that B-cell-specific trophic factors, includ-
ing BSF (B-cell stimulation Factor), BCGF
(B-cell growth factor), and BCDF (B-cell
differentiation factor) had been described
in the supernatants of activated T cells.
The cloning at DNAX, our sister insti-
tute acquired by Schering–Plough, of a
cDNA encoding BSF-1, later renamed IL-
4, in mouse (4) and in human (5) was a
first step forward to the definition of the
molecules controlling B-cell growth and
differentiation. In our laboratory, based
in Dardilly near Lyon (France), we found
that cultured purified human B-cells trig-
gered with anti-B-cell receptor (BCR) and
IL-4 resulted in significant B-cell prolifer-
ation as measured by tritiated thymidine
counts, a common way of measuring B-
cell proliferation in the 1980–1990s (6).
These cultures yielded more B-cells than
did naïve cultures or those exposed to anti-
BCR alone or IL-4 alone. Yet, these cul-
tures established with anti-BCR plus IL-4
yielded less viable B-cells than were input.
Thus, we, B-cell biologists had not yet
been able to reproduce with B-cells the
factor-dependent growth of T cells that our
colleagues T-cell biologists have been able
to achieve.
FEEDER CELLS AND NEW
MONOCLONAL ANTIBODIES YIELD
MORE ROBUST B-CELL CULTURES
A possible explanation for our lack of
success was the absence of feeder cells,
which had become part of the T-cell
culture system and proved necessary to
allow for the expansion of human T-cell
lines and clones. Meanwhile, Kevin Moore
and his colleagues at DNAX, cloned a
human cDNA coding for FcγRII/CD32
and found that FcγRII/CD32-transfected
fibroblast cell lines could present mono-
clonal antibodies in a manner that allowed
for cross-linking of the target molecule
of the relevant cell (7, 8). More specifi-
cally, antibodies to the T-cell CD3 com-
plex presented by these transfected cells
together with IL-2 could induce prolonged
T-cell proliferation (9). Thus, we won-
dered whether the presentation of mon-
oclonal antibodies specifically directed at
B-cell surface molecules in the presence
of B-cell tropic cytokines would lead to
the proliferation and expansion of B-
cells.
By the end of the 80s, we, investigators
from Schering–Plough/DNAX had cloned
cDNAs encoding human GM-CSF (10),
IL-4, IL-5 (5, 6), and FcgR/CD32 (8). We
had also generated a number of mono-
clonal antibodies that would recognize B-
cells including a CD40 antibody (11) and
an anti-B7 antibody now known as CD86
(12). When Paolo de Paoli came to our lab
to perfect his flow cytometry skills, he took
a side project to refine methods for cultur-
ing sorted B-cells using both classical and
new approaches, including the addition of
a feeder-layer of CD32/FcγR-transfected
cells as discussed above (9).
To this end, 96-well-plate microwells
were first seeded with the irradiated fibrob-
last line. A few thousand B-cells were then
added along with a few selected mono-
clonal antibodies with or without IL-2 or
IL-4. Cultures were harvested 3–5 days later
after a brief pulse with tritiated thymi-
dine. It very quickly became apparent that
the combination of the CD40 antibody
Mab 89 (11) and IL-4 could induce unusu-
ally strong B-cell proliferation. The well-
known CD40 antibody G28-5 made by Ed
Clark and Jeff Ledbetter also proved highly
effective in this system (13, 14). Curi-
ously, IL-2 was unable to enhance CD40-
induced B-cell proliferation, although it
did enhance the proliferation of B-cells
activated through their BCR. Furthermore,
the fibroblast layer provided some feeder
effect, as cross-linking the CD40 antibody
on plastic was never as effective in inducing
prolonged B-cell proliferation as present-
ing it with the CD32-transfected fibroblast.
NEW SYSTEM INCREASED B-CELL
PROLIFERATION AND ENABLED
LONG-TERM B-CELL CULTURE AND
STUDIES OF B-CELL DIFFERENTIATION
The next critical experiment was to deter-
mine whether these culture conditions
actually increased the output of B-cells.
Indeed, it was very rewarding to find that
the cultures made with CD40 antibody and
IL-4 did generate more B-cells than were
initially seeded. Subsequent experiments
showed that with this new method we could
establish proliferative B-cell cultures using
relatively low numbers of B-cells (5,000
or less per well) compared to our previ-
ous purified B-cell cultures triggered with
anti-BCR (20,000–50,000 per well). This
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important finding, however, was not the
end of the story, as we still had to show
that this novel B-cell culture system would
allow for the long-term growth (i.e., at least
3 weeks), of B-cells following splitting and
feeding.
Some human B-cells harbor the
Epstein–Barr virus (EBV), which, upon
reactivation, can induce the generation of
factor-independent lymphoblastoid B-cell
lines. Thankfully, removal of the CD40
antibody and IL-4 quickly resulted in B-cell
death. Furthermore, the factor-dependent
B-cell lines failed to express EBNA-2
(Epstein–Barr Nuclear Antigen 2). These
two findings led us to conclude that we
were indeed generating factor-dependent
human B-cell lines (15).
As is so often the case, novel method-
ologies enable us to address a whole new
set of questions. We were thus wondering
whether this new, feeder-layer/monoclonal
antibody-based culture system would per-
mit us to mimic many of the events
happening in the germinal center where
isotype switch, somatic mutations and dif-
ferentiation into either memory B-cells or
plasma cells are thought to occur (16).
Indeed, Yong-Jun Liu and Ian McLennan
showed that CD40-ligation prevents the
spontaneous apoptosis of human centro-
cytes, which undergo antigen-driven selec-
tion within germinal centers (17). Our
later studies and those from others demon-
strated that CD40-activated B-cells could
undergo isotype switch toward IgE when
exposed to IL-4 or IL-13 (18, 19). Upon
exposure to IL-10, CD40-activated B-cells
switch toward IgG1 and IgG3 as well as
IgA1 and IgA2 (20). The combination of
IL-10 and TGFβ further enhances the IgA2
response. The critical studies led with the
CD40 antibodies led to the cloning of it
ligand (CD40-L), a molecule transiently
expressed on T cells, by investigators at
Immunex (21). The importance of CD40–
CD40-L interactions in isotype switching
in humans was further established when
patients devoid of functional CD40-L were
shown not to display switched isotypes
(22–25). In further studies using CD40-
L-transfected fibroblasts, rather than the
combination of CD32/FcγR-transfected
fibroblasts and CD40 antibody, we could
show that CD40-ligation induces germinal
center B-cells to differentiate into memory
B-cells rather than plasma cells (26). Thus,
this new culture method could robustly
recapitulate key features of the germinal
center and thus enable greater insight into
the events leading to B-cell differentiation
than previous approaches.
EXPLOITING THE NEW B-CULTURE
SYSTEM FOR GENERATING HUMAN
MONOCLONAL ANTIBODIES
A practical application of the CD40-system
has been the efficient generation of human
monoclonal antibodies. We eventually sim-
plified the system to the point where
peripheral blood cells (about 5,000 per
well) from individuals displaying selected
antibody specificities in their serum were
simply cultured over CD40-L-expressing
fibroblasts in the presence of exogenous
EBV. Analysis of culture supernatants after
10 days eventually revealed the presence of
antibodies of the desired specificity. This
allowed us to generate large a number
of monoclonal antibodies, such as those
against the Bullous Pemphigoid Antigen1
(27), and against allergens, such as those
from birch pollen (28). Nearly all these
lines proved to be easy to generate; how-
ever, one set of autoantibodies gave us
a hard time: autoantibodies against IL1α,
which we previously found were expressed
in about 10% of the healthy population.
We generated dozens of B-cell lines produc-
ing anti-IL1α antibodies but had difficulty
cloning them. We eventually isolated a sin-
gle clone (29) that produced a high affin-
ity (Kd~10−10) neutralizing monoclonal
antibody. The reason why the cloning of
the lines generating these monoclonal anti-
bodies suggested to us that IL1α might
have a critical role in B-cell expansion,
an hypothesis we could not confirm. A
strategic decision by the Schering–Plough
leadership resulted in the discontinuation
of our human monoclonal antibody pro-
gram in 1994 around the time that the FDA
rejected approval of the anti-sepsis mono-
clonal antibody, Nebacumab, also known
as Centoxin® (30). Today, however, human
monoclonal antibodies are a major suc-
cess in the biotechnology and pharmaceu-
tical world. Several methodologies to gen-
erate monoclonal antibodies are currently
in use. These include: (1) engineering of
mouse monoclonal antibodies, (2) gener-
ating monoclonal antibodies from animals
whose Ig locus has been swapped with
a human Ig locus, (3) the use of phage
display libraries from pools of memory B-
cells, (4) a method similar to ours where
CD40-L cells were replaced by CpG (31),
and (5) the isolation of single B-cells and
the cloning of their heavy and light chains
(32). Other have taken advantage of the
power of the “CD40-system” to generate
long-term B-cell lines that could be used
as highly efficient antigen-presenting cells
to generate autologous antigen-specific T
cells for adoptive immunotherapy (33).
The system can even permit the establish-
ment of long-term porcine B-cell cultures
(34). It is important to know that CD40 is
expressed by a number of cell types other
than B-cells. Most importantly dendritic
cells express CD40 and are activated upon
CD40-ligation (35). A few other cell types
do as well [see Ref. (36)].
In conclusion, this study showed that it
was possible to grow B-cells like T cells
and opened up a path toward obtaining
human monoclonal antibodies and under-
standing B-cell signaling. Before this work,
many labs had tried to get human mon-
oclonal antibodies from EBV transferred
cells but the yields were small and most
often low affinity IgM were generated. I am
indebted in the numerous students and col-
leagues from Schering–Plough and DNAX
who worked with me on these various
projects. The support of Schering–Plough
was essential for these studies.
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